Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney

Experimental Cell Research

Volumn 346, Issue 1, 2016, Pages 99-110

  Sheng, Lili ^a   Yang, Min ^a   Ding, Wei ^a   Zhang, Minmin ^b   Niu, Jianying ^a   Qiao, Zhongdong ^c   Gu, Yong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Aldosterone; Epidermal growth factor receptor; ERK1 2; Profibrotic response; Reactive oxidative stress

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACETYLCHOLINE; ALDOSTERONE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 4; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBRONECTIN; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL COUNT; CELL EXPANSION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FIBROGENESIS; HISTOLOGY; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; UNINEPHRECTOMY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL LINE; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR MATRIX; FIBROSIS; GENETICS; GLOMERULUS; HYPERTROPHY; KIDNEY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TRANSCRIPTION INITIATION;

ALDOSTERONE; ANIMALS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; ERLOTINIB HYDROCHLORIDE; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; HYPERTROPHY; KIDNEY; KIDNEY GLOMERULUS; MALE; MAP KINASE SIGNALING SYSTEM; MESANGIAL CELLS; MICE; MODELS, BIOLOGICAL; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84994860289     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.06.009     Document Type: Article

References (40)

1. [1] Remuzzi, G., Perico, N., Macia, M., Ruggenenti, P., The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 6899 (2005), 57–65.
2. [2] Kelly, T.N., Raj, D., Rahman, M., et al. The role of renin-angiotensin-aldosterone system genes in the progression of chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Nephrol. Dial. Transplant. 30:10 (2015), 1711–1718.
3. [3] Siragy, H.M., Carey, R.M., Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am. J. Nephrol. 31:6 (2010), 541–550.
4. [4] Martín-Fernández, B., Rubio-Navarro, A., Cortegano, I., et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats. PLoS One, 11(1), 2016, e145946.
5. [5] Cortinovis, M., Perico, N., Cattaneo, D., Remuzzi, G., Aldosterone and progression of kidney disease. Ther Adv. Cardiovasc. Dis. 3:2 (2009), 133–143.
6. [6] Lu, Y., Ku, E., Campese, V.M., Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr. Hypertens. Rep. 12:4 (2010), 303–306.
7. [7] Thomas, W., Dooley, R., Harvey, B.J., Aldosterone as a renal growth factor. Steroids 75:8–9 (2010), 550–554.
8. [8] Remuzzi, G., Cattaneo, D., Perico, N., The aggravating mechanisms of aldosterone on kidney fibrosis. J. Am. Soc. Nephrol. 19:8 (2008), 1459–1462.
9. [9] Bomback, A.S., Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety. Blood Purif. 41:1–3 (2016), 166–170.
10. [10] Hollenberg, N.K., Aldosterone in the development and progression of renal injury. Kidney Int. 66:1 (2004), 1–9.
11. [11] Brem, A.S., Morris, D.J., Gong, R., Aldosterone-induced fibrosis in the kidney: questions and controversies. Am. J. Kidney Dis. 58:3 (2011), 471–479.
12. [12] Lai, L., Chen, J., Hao, C., Lin, S., Gu, Y., Aldosterone promotes fibronectin production through a smad2-dependent TGF-β1 pathway in mesangial cells. Biochem. Biophys. Res. Commun. 348:1 (2006), 70–75.
13. [13] Huang, S., Zhang, A., Ding, G., Chen, R., Aldosterone-induced mesangial cell proliferation is mediated by EGF. Recept. Trans. AJP: Ren. Physiol. 296:6 (2009), F1323–F1333.
14. [14] Chen, J., Chen, J., Nagai, K., et al. EGFR signaling promotes TGF beta-dependent renal fibrosis. J. Am. Soc. Nephrol. 23:2 (2012), 215–224.
15. [15] Cheema, M.U., Poulsen, E.T., Enghild, J.J., et al. Aldosterone and angiotensin II induce protein aggregation in renal proximal tubules. Physiol. Rep., 1(4), 2013, e64.
16. [16] Ding, W., Yang, L., Zhang, M., Gu, Y., Reactive oxygen species-mediated endoplasmic reticulum stress contributes to aldosterone-induced apoptosis in tubular epithelial cells. Biochem. Biophys. Res. Commun. 418:3 (2012), 451–456.
17. [17] Xu, C., Ding, W., Yang, L., et al. Contributions of endoplasmic reticulum stress and reactive oxygen species to renal injury in aldosterone/salt-induced rats. Nephron Exp. Nephrol. 126:1 (2014), 25–32.
18. [18] Hackel, P.O., Zwick, E., Prenzel, N., Ullrich, A., Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11:2 (1999), 184–189.
19. [19] Forrester, S.J., Kawai, T., O'Brien, S., et al. Epidermal growth factor receptor transactivation: mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev. Pharmacol. Toxicol. 56 (2016), 627–653.
20. [20] Flamant, M., Bollee, G., Henique, C., Tharaux, P.L., Epidermal growth factor: a new therapeutic target in glomerular disease. Nephrol. Dial. Transpl. 27:4 (2012), 1297–1304.
21. [21] Samarakoon, R., Dobberfuhl, A.D., Cooley, C., et al. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species. Cell Signal 25:11 (2013), 2198–2209.
22. [22] Terzi, F., Burtin, M., Hekmati, M., et al. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J. Clin. Investig. 106:2 (2000), 225–234.
23. [23] Liu, N., Guo, J.K., Pang, M., et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23:5 (2012), 854–867.
24. [24] Ding, W., Xu, C., Wang, B., Zhang, M., Rotenone attenuates renal injury in aldosterone-infused rats by inhibiting oxidative stress, mitochondrial dysfunction, and inflammasome activation. Med. Sci. Monit. 21 (2015), 3136–3143.
25. [25] Ding, W., Yang, L., Zhang, M., Gu, Y., Chronic inhibition of nuclear factor kappa B attenuates aldosterone/salt-induced renal injury. Life Sci. 90:15–16 (2012), 600–606.
26. [26] Toyonaga, J., Tsuruya, K., Ikeda, H., et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol. Dial. Transpl. 26:8 (2011), 2475–2484.
27. [27] Chen, S., Meng, X., Zhang, C., Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury. Biomed. Res. Int. 2013 (2013), 1–7.
28. [28] Barrera-Chimal, J., Perez-Villalva, R., Rodriguez-Romo, R., et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int. 83:1 (2013), 93–103.
29. [29] Mathew, J.T., Patni, H., Chaudhary, A.N., et al. Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. AJP: Ren. Physiol. 295:1 (2008), F73–F81.
30. [30] Terada, Y., Kobayashi, T., Kuwana, H., et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J. Am. Soc. Nephrol. 16:8 (2005), 2296–2305.
31. + exchanger isoform 1. Am. J. Nephrol. 31:1 (2010), 75–82.
32. [32] Zhang, M.Z., Wang, Y., Paueksakon, P., Harris, R.C., Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63:6 (2014), 2063–2072.
33. [33] Taniguchi, K., Xia, L., Goldberg, H.J., et al. Inhibition of src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 62:11 (2013), 3874–3886.
34. [34] Nistala, R., Wei, Y., Sowers, J.R., Whaley-Connell, A., Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl. Res. 153:3 (2009), 102–113.
35. [35] Queisser, N., Oteiza, P.I., Stopper, H., Oli, R.G., Schupp, N., Aldosterone induces oxidative stress, oxidative DNA damage and NF-κB-activation in kidney tubule cells. Mol. Carcinog. 50:2 (2011), 123–135.
36. [36] Patni, H., Mathew, J.T., Luan, L., et al. Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. AJP: Ren. Physiol. 293:4 (2007), F1065–F1071.
37. [37] Nishiyama, A., Yao, L., Nagai, Y., et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43:4 (2004), 841–848.
38. [38] Hendron, E., Stockand, J.D., Activation of mitogen-activated protein kinase (mitogen-activated protein kinase/extracellular signal-regulated kinase) cascade by aldosterone. Mol. Biol. Cell 13:9 (2002), 3042–3054.
39. [39] Stockand, J.D., Meszaros, J.G., Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am. J. Physiol. Heart Circ. Physiol. 284:1 (2003), H176–H184.
40. [40] Nagai, Y., Miyata, K., Sun, G.P., et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46:4 (2005), 1039–1045.